Interferon α in the treatment of polycythemia vera
(IFN) inhibits the growth of the abnormal clone in patients with myeloproliferative disorders, leading to a reduction of the clinical and laboratory signs of the pathologic myeloproliferation. The therapeutic efficacy of IFN in polycythemia vera (PV) is demonstrated by the summarized treatment resul...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2000
|
| In: |
Annals of hematology
Year: 2000, Jahrgang: 79, Heft: 3, Pages: 103-109 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s002770050563 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s002770050563
|
| Verfasserangaben: | E. Lengfelder, U. Berger, R. Hehlmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1802599746 | ||
| 003 | DE-627 | ||
| 005 | 20220820185225.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220519s2000 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s002770050563 |2 doi | |
| 035 | |a (DE-627)1802599746 | ||
| 035 | |a (DE-599)KXP1802599746 | ||
| 035 | |a (OCoLC)1341460230 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lengfelder, Eva |d 1951- |e VerfasserIn |0 (DE-588)1031229779 |0 (DE-627)736022775 |0 (DE-576)378669230 |4 aut | |
| 245 | 1 | 0 | |a Interferon α in the treatment of polycythemia vera |c E. Lengfelder, U. Berger, R. Hehlmann |
| 246 | 3 | 3 | |a Interferon alpha in the treatment of polycythemia vera |
| 264 | 1 | |c March 2000 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.05.2022 | ||
| 520 | |a (IFN) inhibits the growth of the abnormal clone in patients with myeloproliferative disorders, leading to a reduction of the clinical and laboratory signs of the pathologic myeloproliferation. The therapeutic efficacy of IFN in polycythemia vera (PV) is demonstrated by the summarized treatment results of 279 patients participating in 16 prospective nonrandomized studies and in three case reports. The initial IFN dose ranged from 3 to 35 million IU/week. In 82% of the patients the frequency of phlebotomies was reduced. In 50% a complete remission was achieved, defined as a stable hematocrit of 45% without concomitant phlebotomies. Reduction of splenomegaly was seen in 77% and control of pruritus in 81% of the patients. The median observation time of the studies was 13 months (ranging from 3 to 84 months). Individual cases were followed for up to 126 months. In 21% of the patients IFN was terminated, owing mostly to side effects. The selective suppression of the malignant clone by IFN was demonstrated by the induction of cytogenetic remissions in sporadic cases with a chromosomal marker and by the observation of unmaintained remissions that lasted up to 4.8 years. IFN has no known mutagenic or teratogenic effects. The data presently available demonstrate that IFN is an effective alternative to the present forms of treatment in PV. Controlled prospective studies are essential to clarify whether the favorable biologic properties are also reflected by a benefit in clinical course and survival, and whether IFN may reduce the rates of acute leukemia and myelofibrosis. A randomized study that compares IFN and hydroxyurea in patients with PV has recently been initiated by the Süddeutsche Hämoblastosegruppe (SHG) in Germany. | ||
| 650 | 4 | |a Induction therapy | |
| 650 | 4 | |a Interferon α | |
| 650 | 4 | |a Long-term treatment | |
| 650 | 4 | |a Polycythemia vera | |
| 650 | 4 | |a Side effects | |
| 700 | 1 | |a Berger, Ute |e VerfasserIn |0 (DE-588)1255399929 |0 (DE-627)1799635341 |4 aut | |
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1991 |g 79(2000), 3, Seite 103-109 |h Online-Ressource |w (DE-627)253389852 |w (DE-600)1458429-3 |w (DE-576)072283157 |x 1432-0584 |7 nnas |a Interferon α in the treatment of polycythemia vera |
| 773 | 1 | 8 | |g volume:79 |g year:2000 |g number:3 |g pages:103-109 |g extent:7 |a Interferon α in the treatment of polycythemia vera |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s002770050563 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220519 | ||
| 993 | |a Article | ||
| 994 | |a 2000 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |d 61200 |e 60000PH1037003489 |e 61200PH1037003489 |k 0/60000/ |k 1/60000/61200/ |p 3 |y j | ||
| 998 | |g 1255399929 |a Berger, Ute |m 1255399929:Berger, Ute |d 60000 |d 61200 |e 60000PB1255399929 |e 61200PB1255399929 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 1031229779 |a Lengfelder, Eva |m 1031229779:Lengfelder, Eva |d 60000 |d 61200 |e 60000PL1031229779 |e 61200PL1031229779 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1802599746 |e 4136190786 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2000","dateIssuedDisp":"March 2000"}],"relHost":[{"disp":"Interferon α in the treatment of polycythemia veraAnnals of hematology","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Hematology"}],"language":["eng"],"part":{"year":"2000","volume":"79","extent":"7","pages":"103-109","issue":"3","text":"79(2000), 3, Seite 103-109"},"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"pubHistory":["62, 1 (Februrary 1991)-"],"title":[{"title":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title_sort":"Annals of hematology"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1432-0584"],"eki":["253389852"],"zdb":["1458429-3"]},"origin":[{"publisherPlace":"Berlin ; Heidelberg ; New York","dateIssuedKey":"1991","dateIssuedDisp":"1991-","publisher":"Springer"}],"recId":"253389852"}],"id":{"doi":["10.1007/s002770050563"],"eki":["1802599746"]},"physDesc":[{"extent":"7 S."}],"title":[{"title":"Interferon α in the treatment of polycythemia vera","title_sort":"Interferon α in the treatment of polycythemia vera"}],"person":[{"role":"aut","family":"Lengfelder","given":"Eva","display":"Lengfelder, Eva"},{"role":"aut","family":"Berger","display":"Berger, Ute","given":"Ute"},{"role":"aut","family":"Hehlmann","display":"Hehlmann, Rüdiger","given":"Rüdiger"}],"recId":"1802599746","name":{"displayForm":["E. Lengfelder, U. Berger, R. Hehlmann"]},"titleAlt":[{"title":"Interferon alpha in the treatment of polycythemia vera"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 19.05.2022"],"language":["eng"]} | ||
| SRT | |a LENGFELDERINTERFERON2000 | ||